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INTRODUCTION
The idea that medicinal products may be found from the extracts of 
marine animals is not new.1’2 Thus, it is worth spending considerable 
time and effort on developing accurate assays to test relatively pure 
compounds that are suspected of having biological activity. Before this, 
however, crude extracts must be screened to give at least a qualitative 
measure of the amount of activity a sample may possess. Also, so that 
the assay may be used in the field to give the researcher an idea of which 
organisms to collect, the assay must be relatively easy to perform, 
relatively fast, and the equipment must be compact. One such a;say is the 
frog heart assay. The potential of detecting cardioactivity of marine 
natural products has been realized in recent years through the discovery 
of toxins of the sea anemones A n e m o n ia  s u lc a ta . A n th o o le u ra
xanthoaram m ica. and Anthopleura__elegantissima.3 all members of the
Coelenterata phylum. The toxicity of such animals from either contact or 
ingestion has been known for many years, thus it is not surprising that 
they have captured the interest of pharmacologists.4 Three different 
toxins, ATXI, ATXII, and ATXIII, have been isolated from Anemonia sulcata 
and exhibit varying degrees of biological activity.5 Studies with mice 
have shown that the dosage lethal to 50% of the mice tested needs to be 
about 25 times greater for ATXI than ATXII. Post mortem examinations of 
there mice have shown contracture of the heart, indicating cardiotoxic 
action of these toxins.4 Such tests indicate that ATXII is about 100-300 
times as effective as ATXI on left atria of guinea pigs and rats.3*4 Upon 
further investigation, ATXII was found to exhibit a positive inotropic 
effect without destroying the ATPase, making it superior to the cardiac 
g lycos ides.3-4-5 Extracts of both Anthopleura xanthogram m ica and
Anthopleura elegantissima have shown a strong positive inotropic effect 
yet no chronotropic effect. As with the ATX toxins, it was found that the 
sodium-potassium ATPase was not inhibited.4.
The frog heart assay used in this experiment was initially developed 
by Prosser and Shain at the University of Illinois, and has been modified 
by Traeger and, again, by Catlow.6'7 There are several advantages to 
using a frog’s heart. First, the frog's heart will survive for hours if placed 
in a bath of well-oxygenated Krebs solution. This relieves the burden of 
having the heart constantly needing to be perfused in blood as with a 
mammal's heart.8 Also, the price of a frog is relatively low, and they are 
easier to care for than mammals or most other laboratory animals. 
Theoretically, the assay should be a successful means of screening for 
possible cardiac drugs for humans as the frog's heart has been shown to 
react similarly to a human heart to certain cardiac drugs.9 It has also 
been found that the metabolism of the frog's heart is similar to that of a 
mammalian heart.8 This assay is not without limitations, however. For 
example, because the assay is not performed on the entire living animal, 
it is not known what other physiological effects the concentration 
necessary to elicit a cardiac response will have. On the other hand, 
because a whole heart is used as opposed to a piece of muscle, toxicity 
effects of samples are increased. Also, because the reversibility of 
binding of extracts to the frog's heart is not known, a new frog's heart 
must be used for each trial. This will tend to increase error and must be 
corrected by doing several trials of the same sample. Also, the 
metabolism of the frog's heart is sensitive to both days in captivity and 
temperature of the surroundings.8 Although it is relatively easy to
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control the temperature, it is more difficult to keep the length of 
captivity of each frog constant.
Previously, the results of this assay have not proven to be very 
promising. The main problem is that the assay was shown not to be 
reproducible within acceptable limits. Indeed, some extracts were shown 
to elicit a positive increase in heart rate in one trial and a negative 
response in another. The focus of this research endeavor was to make the 
frog heart assay reliable enough to screen crude extracts for 
cardioactivity in order that they could be purified and identified. It is 
instructive, however, to first have a knowledge of the general physiology 
of the heart and the modes of action of some classic neurotransmitters 
and drugs.
BACKGROUND
A. Physiology of the Heart
The heart is mostly made up of cardiocytes, which are the muscle 
cells of the heart. Tissues which make and propagate electrical activity , 
made of "pacemaker cells", compose the rest of the heart. Each cardiocyte 
is bounded by the sarcolemrna, which is a bilayered phospholipid- 
containing structure. The sarcolemrna is filled with bundlos of 
myofibrils, which are the contractile units of the cardiocytes.10 
Myofibrils are composed of sarcomeres, which are the functional units of 
the heart (Figure 1). During contraction, the Z-lines move together while 
the I and H bands decrease in size. The A-band remains the same size 
throughout contraction. Troponin and tropomyosin are important 
regulatory proteins for contraction and will be discussed shortly.11
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FIGURE : 1
THE STRUCTURE OF A SARCOMERE
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The "pacemaker cells" make up the origin of the electrical activity of 
the heart. These cells are in the sinoatrial (S-A) node, which may 
spontaneously generate a beat, thus differentiating heart muscle from 
skeletal muscle.10 This electrical activity goes quickly from the 
sinoatrial node to the atrioventricular (A-V) node and then through the 
bundle of His to the Purkinje fibers. The Purkinje cells, with their tight 
packing and intercalated discs, allow the heart to act as a synchronous 
unit.1 ° ’11
Once the current reaches the cardiocytes, the electrical activity is 
converted to mechanical activity via several ion pumps and channels 
located in the sarcolemma. One of the most studied of these pumps is the 
sodium-potassium pump or the sodium-potassium ATPase, as it utilizes 
ATP as its form of energy. The sodium-potassium ATPase is a globular 
protein which penetrates through the entire lipid bilayer of the 
sarcolemma. When bound by either a potassium iori or sodium ion, a 
conformational change occurs which then activates the ATPase.10 The 
pump actively transfers three sodium ions to the outside of the cell for 
every two potassium ions pumped into the cardiocyte. This sets up an 
electrochemical gradient.12
A voltage-gated calcium ion channel, which is coupled to a sodium ion 
channel, is also present in the saicolemma and is the main entrance for 
calcium ions into the cardiocytes. These calcium channels are opened due 
to a change in voltage across the membrane due to the opening of the 
sodium channel.10 Although the amount of calcium ions entering the cell 
in this fashion is rather small relative to the amount of calcium in the 
cell, it is generally believed that it is the rate of change of calcium ion 
concentration which is vital in the contraction mechanism.11-13
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The contraction of the heart is due primarily to the contractile 
proteins actin and myosin, and the regulatory proteins troponin and 
tropomyosin. Contraction depends on the ability of myosin to bind to 
actin. Tropomyosin if  an alpha-helical protein wound around actin. 
Troponin is bound to the tropomyosin and has a site for binding calcium 
ions and a site inhibiting the binding of myosin to actin. When the 
concentration of calcium rises in the cytosol, the calcium ions bind to 
their respective sites on the troponin giving rise to a conformational 
change in both troponin and tropomyosin. This change in conformation
uncovers the binding site for myosin on actin and contraction 
proceeds.11'14
The sarcoplasmic reticulum (SR) is an organelle of the cardiocyte 
which is very important in the contractile mechanism. Its main function 
is the regulation of the supply of calcium ions to the sarcomeres. During 
contraction (systole) the cytosolic calcium ion concentration (i.e. the 
concentration inside the cell yet outside the SR) is relatively high, and 
during relaxation (diastole) this concentration is relatively low.15 This 
change in calcium ion concentration may be attributed to the SR as it is 
rich in calcium, yet its concentration of calcium ions has been shown to 
decrease before contraction.11 The calcium pump of the SR is regulated 
by phospholamban, a phosphoprotein embedded in the membrane. 
Phospholamban, upon phosphorylation by ATP, will increase the activity of 
the pump. The mechanism governing this reaction is not well 
understood.10 Also, it has been proposed that the calcium ions binding 
troponin come from the SR and that the calcium ions transported through 
the sarcolemma aid in the SR discharge. This mechanism is known as 
calcium-induced calcium release.13
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The ability of membranes to increase spontaneously their 
permeability to sodium and potassium ions provides the basic mechanism 
of excitation of the heart. The cardiac cycle through systole and diastole 
shows the electrophysiological changes and is divided into five main 
phases. The resting potential is determined by the potassium ion gradient, 
which has a resting potential of -90 mV, as it is more permeable than 
sodium when the muscle is in its resting state. The combination of phases 
1 and 2 make up the absolute refractory period during which the heart may 
not bo stimulated. Phase 3 is also known as the relative refractory period 
during which a very strong stimulus may excite the tissue. After phase 3 
there is a period of supernormal excitability such that a very weak 
stimulus may excite the heart.16
B. Pharmacology of the Heart
Pharmacology is generally based on a hormone-receptor theory. The 
models for such a mechanism are analogous to the enzymatic models 
known as the "lock-and-key” model and the "induced fit model". For the 
former, the agonist molecule (i.e. hormone or drug used to elicit the 
desired response) is considered as the key, while the receptor is thought 
of as the lock. The induced fit analog states that the agonist gives rise to 
a change in conformation in the receptor to cause an intracellular 
effect.10
Antagonist molecules are those molecules which interfere with the 
binding of the agonist and its receptor. This interference could be for the 
same site (competitive inhibition) or for a different site on the 
receptor.10 Also, the degree to which the antagonist interferes with the 
agonist depends on their respective binding constants.17
8Although these aforementioned models provide convenient 
mechanisms for the action of hormones and drugs, they are far from 
complete. For example, neither model is able to account for the almost 
''all-or-none" effect of a particular agonist. The allosteric theory, which 
postulates that the agonist changes the conformation of the receptor in 
such a way as to impede further agonist binding, attempts to correct for 
this. Otherwise, the maximum effect of an agonist would come from 
maximum occupancy of the receptor. The dose-response curve, by plotting 
the effect of an agonist versus concentration of that agonist, shows quite 
explicitly that a small change in concentration may lead to a large change 
in response.10
The mechanisms of the effects of hormones and drugs on the heart is 
readily explained by considering the second messenger concept. In this 
model, the signal of the agonist is called the first messenger, and the 
second messenger acts within the cell as it is formed at the 
membrane.The second messenger may produce cascade effects in that only 
a small amount is needed to elicit many different responses. As these 
responses give rise to other responses it is easy to see the great effect of 
just one messenger. This concept is used to explain the modes of action 
of both neurotransmitters and cardiac drugs.10
Only some effects of some catecholamines may be explained by the 
second messenger concept. For example, some catecholamines, upon 
stimulation of receptors of pacemaker cells as part of the sympathetic 
nervous system, increase the electrical impulse of the S-A node. This has 
the effect of increasing the heart rate as conduction of the A-V node is 
also enhanced.18 This positive chronotropic effect is representative of 
the catecholamines, but is more of an indirect effect than that brought
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about by a second messenger. However, the positive inotropic effect 
(increased force of contraction), also representative of catecholamine 
stimulation, is readily explained by considering second messengers. In 
this case, the second messenger is cyclic adenosine monophosphate 
(cAMP), which is derived from ATP via the enzyme adenylate cyclase.10 
The stimulation of beta-adrenergic receptors by some catecholamines 
activates adenylate cyclase, thus producing cAMP. Inactive protein 
kinases are activated upon interaction with cAMP. The mechanism of the 
positive chronotropic effect is now easily imagined: the active protein
kinases may aid in phosphorylating phospholamban to facilitate calcium 
release from the sarcoplasmic reticulum (Scheme 1).19 The clinical uses 
of catecholamines include treatment for shock occurring from reduction 
of cardiac contractility, or A-V node conduction block.16
Norepinephrine, a catecholamine which is an extremely important 
neurotransmitter, is released from sympathetic nerve-end stores in 
emergency situations.12 It is derived in the body from tyrosine; Scheme 2 
shows the structural similarity of tyrosine, norepinephrine and 
e p in e p h rin e .20 The half-life of norepinephrine is rather short, thus 
lending to its importance as a quick, short lived stimulator. Its effects on 
the body are seen only a few minutes after clinical administration.16 The 
sympathetic division of the autonomous nervous system, due to the 
releasal from the adrenergic nerve-ends, is said to prepare the body for 
"flight or fight" .12
The other division of the autonomic nervous system, the 
parasympathetic division, is sometimes called the cholinergic nervous 
system. It is this system which gives rise to both negative chronotropic 
and inotropic responses, and a decrease in the conduction velocity of the
CAMP
active protein 
kinase
SCHEME 1: POSSIBLE MECHANISM FOR POSITIVE INOTROPIC EFFEC P OF CATECHOl AMINES
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SCHEME 2 : STRUCTURES OF TYROSINE, NOREPINEPHRINE, AND EPINEPHRINE
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A-V node.10-18 The main neurotransmitter of this system is 
acetylcholine. Chcline may be converted to acetylcholino in the presence 
of acetylcholine transferase and acetyl CoA (Scheme 3).18 The cholinergic 
receptor of acetylcholine with respect to its effects on the heart is the 
muscarinic receptor, which acts on the vagus nerve. Stimulation of these 
nerve endings gives rise to the negative inotropic effect. It is also known 
that atropine is an effective blocking agent of the muscarinic receptor.18 
Acetylcholine is not readily administered as a cardiac drug, but its 
implications are important due to the cholinergic-like actions of some 
glycosides and anti-arrhythmic agents.16-18
The cardiac glycosides, or digitalis glycosides, were recognized to 
have medicinal effects before 1500 B.C..16 The glycosides contain an 
aglycone moiety joined to a number of sugar molecules at the C3 position. 
Two typical glycosides, digoxin and digitoxin, are pictured in Scheme 4. 
The two main effects of digoxin therapy are a positive inotropic effect 
and a negative chronotropic effect.18 The mechanism of action giving 
rise to the positive inotropic effect is rather controversial, though one 
model has been most widely accepted. It is known that there is a
relatively high affinity, high specificity interaction between glycosides 
and the sodium-potassium ATPase inhibitory site.21 Therefore, it has 
been proposed that glycosides act by inhibiting this pump and thus 
allowing a buildup of cytosolic sodium ions. To relieve this added stress, 
the sodium ions may leave by means of the sodium channel; but as this is 
coupled to the calcium channel, calcium ions will enter the car- 
d iocyte.16-18 As stated, this change in calcium concentration, albeit 
small, may cause the sarcoplasmic reticulum to release a relatively high 
concentration of calcium ions, thus increasing contraction (Scheme 5).
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SCHEME 3 : CONVERSION OF CHOLINE TO ACETYLCHOLINE
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DIGOXIN : R -  OH 
DIGITOXIN : R = H
SCHEME 4 : THE STHUCTURES OF DIGOXIN AND DIGITOXIN
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SCHEME 5 : POSSIBLE MECHANISM FOR POSITIVE INOTROPIC EFFF.C I' OF DIGOXIN
The negative chronotropic effect is said to come from decreased 
conduction through the A-V node. This is accomplished by the indirect 
vagal stimulation representative of the glycosides, as they allow the 
release of acetylcholine.18 For this to be true, the increase in force of 
contraction from the glycosides must be greater than the response to 
acetylcholine as it generally causes a negative inotropic response.
A major problem with the clinical application of cardiac glycosides is 
that there is a fine line between therapeutic and toxic doses of these 
drugs.21 As a matter of fact, it is generally believed that the therapeutic 
doses negatively affect the heart, though not to the extent of cardiac 
a rrest.18 This gives added interest in developing ATX as a cardiac
medication. Obviously, then, if these types of drugs are to be considered, 
the benefits must surpass the ill effects. Digitalis compounds are quickly 
being replaced by drugs such as dopamine for the treatment of acute heart 
failure; but for chronic heart failure, it is still the drug of choice.22
Other drugs for the heart include anti-arrhythmic drugs, beta- 
adrenergic blocking agents, hypotensive drugs, vasodilators, calcium 
antagonists, and nitrates.22-23 As these agents were not immediately 
relevant to the present research, a description of their mechanisms and 
uses will not be included.
EXPERIMENTAL
The recording instrument first used by Catlow was a single channel 
minirecorder along with a graphic driving amplifier (GDA).7 The GDA 
proved to be inadequate as it did not have the capacitance to properly 
filter the signals. This showed up as an exponential loss of power which 
could mistakenly lead one to believe that the force of contraction of the
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frog’s heart was decreasing. A new amplifier was made by Reiner at the 
University of Illinois. A new linear 1200 recorder was used when the 
minirecorder began to malfunction. Although it was eventually repaired, 
it was no longer used as the 1200 is a superior recorder. The Grass FT .03 
force transducer, which had been used in previous years, was used 
throughout this experiment.
The Plexiglass chamber was chosen for its compact size, lending 
itself well for work in the field. A small hole was drilled in one side to 
fit a hook on which to secure one end of the heart. Another hook was 
attached to the transducer to fix the other end of the heart. The 
experimental set-up is illustrated in Figure 2.
The chamber, or bath, was filled (30 mL) with Krebs solution, which 
consists of 89.5 mM NaCI, 3.0 mM KCI, 3.0 mM NaHCC>3, 3.0 mM D-glucose, 
2.5 mM CaCl2 , and 1.0 mM MgS04  in distilled water. This solution was 
stored in a cold room (50 °F) when not in use to slow sugar degradation. 
Before an assay, the solution was sufficiently oxygenated with a 95:5 
oxygen:carbon dioxide mixture.
The frog under study was the leopard frog, Rana pipiens pipiens. The 
size of the frogs usually varied between 3 and 31/2 inches although 
smaller frogs were sometimes used if they were all that was available. 
The frogs were kept in a cold room (50 °F) when not needed as this kept 
their metabolism low, thus making it much easier to care for them.
To perform an assay a frog would first be decapitated and its spinal 
cord pithed. The frog is then placed on its back, and both the skin and 
underlying layer of tissue were cut down the middle of the frog. Two 
horizontal cuts were made near the top of the thoracic cavity so that the 
heart was exposed. The pericardium, which is the transparent layer of
17
(NOT TO SCALE)
FIGURE 2 : THE FROG HEART ASSAY
tissue immediately surrounding the heart, was now carefully cut. Using 
forceps, the heart was taken by the carotid trunk and any attached tissue 
was cut. The heart was then placed in a container of well-oxygenated 
Krebs solution so that the heart could clear itself of blood. Once 
accomplished, the heart was pierced on both sides of the ventricle with 
tiny glass hooks with thread tied to them. The heart was now positioned 
in the bath so that the beating heart provided enough tension in the 
threads to show a strong response on the recorder, though not so much as 
to over stretch the tissue. The heart was now allowed to stabilize such 
that the change in frequency and amplitude over time was zero. This 
generally took fifteen to twenty minutes. At this time a sample was 
introduced to the bath. The crude extracts were prepared by grinding 2 g 
of a specimen in 20 ml_ of 3:1 : methanol:toluene solution. This solution 
was stored below 0 °C when not used as the crude extracts were of 
unknown composition, thus the degree to which any components of the 
extract were sensitive to heat was not known .
RESULTS
The results of assays initially performed in order to reproduce 
previous data are given in Table 1. Data from assays testing the effects 
of norepinephrine bitartrate and digoxin are given in Tables 2 and 3, 
respectively. Also, dose-response curves were made for each of these 
drugs, as well as a graph showing the decomposition of norepinephrine 
over a one day period (Figures 3-5).
Results of assays testing sea urchins and sea anemones collected 
from Maine in 1986 are given in Table 4. Different fractions of the sea 
urchin 28-VI-86-1-5 were taken and tested. Results of these assays are
19
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TABLE 1
INITIAL ASSAYS TESTING POTENTIALLY CARDIOACTIVE 
EXTRACTS (IBE 1983, INAE 1985 AND INAE 1986)
S A M PLE #
28-VII-86-1-5
28- VII-86-1 -5 
3-VIII-86-1 -9 
3-VIII-86-1-9 
3-VIII-86-1 -6
29- VII-86-1 -10 
12-VI-83-1 -3 A 
12-VI-83-1-3B 
3-VIII-86-1 -5
3-VIII-86-1-9 
3-VIII-86-1 -9 
29-VII-86-1 -10 
12-VI-83-1-3A 
12-VI-83-1-3B 
28-VII-86-1-5
28- VII-86-1-5 
3-VIII-86-1 -5 
3-VIII-86-1-5 
6-VII-85-3-7
29- VII-86-1 -10 
8-VI-83-1 -3 
8-VI-83-1-16
% CHANGE IN 
FREQUENCY 
(AFTER 15 MIN.)
•30.3
•30.0
•58.5
•13.5
•33.0
-25.0
•36.4
- 68.6
•62.2
-41.9
-54.3
-45.7
-35.5
-18.5
-35.0
-27.0
•21.9
•25.0
•29.4
-30.0
•50.0
-77.4
% CHANGE IN 
INTENSITY 
(AFTER 15 MIN.)
-75.0 
0.0 
+ 16.7 
+16.7 
- 66.0 
+45.0 
-58.0 
-72.0 
-26.7
-26.9
-42.4
-88.9
+4.0
•33.3
-66.7
- 20.0
-8.3
-25.0
-60.0
- 10.0
-57.6
-51.7
COMMENTS
A. STEEL HOOKS
sea urchin 
sea urchin
sea urch in
M urlcanthus
prlnceps
B. GLASS HOOKS
M urlcan thus 
p rlnceps 
sea u rch in  
sea urch in
Haliciona
A p lld lum
Neorapana
tubercu la ta
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TABLE 2
DATA USING NOREPINEPHRINE BITARTRATE
CONC I MAXIMUM POSITIVE CHANGE(%) » OVERALL CHANGE(%)
MOLARITY F I  F I
10 '3 64.0 30.0 0.0 -61.6
5x1 O'4 40.0 68.8 8.9 18.8
It 50.3 17.3 23.7 -34.0
H 52.1 — 21.6 —
It 52.9 21.8 8.8 -5.5
M 46.3 87.5 1.0 -29.0
II 54.0 -- 17.0 • •
It 51.5 20.0 30.3 -27.9
It 50.0 29.6 26.7 -29.7
H* 35.1 24.0 21.0 -28.2
M* 38.5 47.0 -5.0 -23.3
30.8 21.8 -12.3 0.0
M* 38.9 13.4 •16.7 -34.8
31.6 63.4 -7.9 +23.2
10‘5 36.0 11.8 12.5 -19.4
10’7 10.4 10.4 -17.3 -1.0
10® 7.5 10.4 -20.0 22.4
10‘9 3.8 0.0 -26.9 -6.3
5x10‘ 4(avg.) 49.6+4.52 40.8+29.8 27.3t9 .54 -17.9+20.6
* n o re p in e p h r in e  s o lu t io n  w a s  one da y  o ld  
-- : no da ta  fo r  th a t p a r t ic u la r  tr ia l 
ch a n g e  fifte e n  m in u te s  a fte r  a d d itio n
22
TABLE 3
DATA USING DIGOXIN
CONC I MAXIMUM POSITIVE CHANGE(%) I OVERALL CHANGE(%)
MOLARITY F I F I
10'3 16.7 0.0 -46.7 -75.6
M 12.2 0.0 -52.7 -72.0
10'4 5.6 0.0 -41.7 •42.7
II 3.8 0.0 -38.8 -94.0
II 6.3 0.0 -34.4 -40.2
II 10.2 0.0 -30.0 -29.5
19 6.3 « -28.0 -12.9
II 7.7 0.0 -30.8 -17.6
10'® 0.0 3.5 -21.6 -30.3
M 0.0 8.2 -20.0 8.2
•i 0.0 6.9 -18.4 -10.3
•i 0.0 8.3 -18.8 -4.5
•i 0.0 - -25.7 -14.3
II 0.0 8.6 -21.4 -8.5
H 0.0 - •16.6 -3.2
10‘7 0.0 - -13.5 --
10'® 2.8 10.8 -27.7 0.0
« r 16 0.0 12.3 -21.2 -9.9
10‘ 18 2.8 18.6 -19.4 -27.8
I 0 '4(avg.) 6 ,64 i2 .15 0.0 34.0+5.4 •39.5+29
I0'® (avg.) 0.0 7.1 + 2.1 -20.3+3.0 -9 .0±11.
-  : no data to r th a t p a rticu la r tr ia l 
change lllte o n  m in u te s  a lte r  a d d itio n
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FIGURE 3 : DOSE-RESPONSE CURVE, NOREPINEPHRINE BITARTRATE
FIGURE 4 : DOSE-RESPONSE CURVE, DIGOXIN
log(conccntration) in M
pe
rc
en
t c
h
an
ge
 in
 f
re
qu
en
cy
2 4
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FIGURE 6 : CHOLINE CHLORIDE AND SEA URCHIN 28-VII-86-1-5
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presented in Table 5. The extraction scheme is given in Scheme 6. Figure 
6 shows the similar responses to choline chloride and 28-VI-86-1-5.
Data from assays performed using choline chloride, acetylcholine 
chloride, atropine, scopolamine, and/or 4-(1 -naphthylvinyl)pyridine are 
given in Tables 6,7. Miscellaneous results from assays with 8,11,14- 
eicosatrienoic acid, tho sea urchin 31-VII-86-3-14, a mixture of the 
three ATX toxins, tunicates from Florida, didemnins B and E, and various 
sponges are given in Table 8.
For the purposes of this paper, the term "intensity" is used in place of 
"amplitude" on all tables and figures. Thus, "I" is used in place of "A".
DISCUSSION
The original goal of this endeavor was to re-test those extracts 
which had been shown to have cardioactivity in previous years. Once these 
results were shown to be reproducible, the rest of the project would 
consist of isolating and purifying the activity. The problem, however, was 
that although some samples had shown promise, the results were never 
sufficiently reproduced. Therefore, only the extracts which had shown a 
50% change in either frequency or amplitude were to be tested. After 
testing several of these (Table 1), it was clear that there was too much 
error. Once the new amplifier was used, an inherent loss of frequency of 
the heartbeats was observed for 45 to 60 minutes after the frog's heart 
was placed in the bath and connected to the transducer. By counting the 
beats without inserting the steel hooks into the heart, it was noticed 
that the addition of DMSO did not cause the frequency loss. The idea that 
perhaps the heart muscle was stretched once set up was discarded as the 
frequency loss was noticed when the hooks were inserted but the heart
25
TABLE 4
DATA FROM SEA URCHINS AND SEA ANEMONES COLLECTED
IN MAINE, 1986 (INAE 1986)
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ORGANISM 1 SAMPLE# 1 MAXIMUM SUDDEN CHANGE(%)
F I
SEA ANEMONE 3-VIII-86-1-8 11.5 0.0
SEA URCHIN 28-VI-86-1-5 10.7 0.0
SEA URCHIN (guts) 31-VII-86-3-14 8.7 0.0
SEA ANEMONE 30-VII-86-2-3 8.1 0.0
SEA URCHIN (sp ines) 31-VII-86-3-14 7.0 -17.2
SEA ANEMONE 29-VII-86-1-6 6.9 8.0
SEA URCHIN 2-VIII-86-1-1 6.3 6.2
SEA URCHIN 29-VIII-86-1 -12 6.1 1.6
SEA ANEMONE 28-VII-86-1-7 6.1 0.0
SEA URCHIN 3-VIII-86-1 -C* 5.0 0.0
SEA ANEMONE 3-VIII-86-1-7 3.4 0.0
SEA ANEMONE 2-VIII-86-2-6 3.3 0.0
SEA ANEMONE 7-VIII-86-1-10 3.2 9.5
SEA URCHIN 7-VIII-86-3-5 3.2 0.0
SEA ANEMONE 7-VHI-86-3-3 2.5 • •
SEA ANEMONE 3-VIII-86-1 -4 0.0 21.6
SEA URCHIN 2-VIII-86-2-5 0.0 0.0
SEA URCHIN 7-VIII-86-1 -2 0.0 ••
• • :  no data for that particular trial 
each sample was approximately 3 mg
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TABLE 5
DATA FROM VARIOUS FRACTIONS OF THE 
SEA URCHIN 28-VI-86-1-5
FRACTIONS , b
methylene chloride trituration
methanol trituration
precipitate
gonads
gonads
gonads
digestive tract
digestive tract
shell
shell
heptane layer of methanohheptane mixture 
polar phase of extraction of methanol layer
non-polar phase of extraction of methanol layer 
100% water fraction through RP-18
II
H20:methanoi (70:30) through RP-18 
100% methanol fraction through RP-18
chloroformimethanol (1:1) through RP-18
MAXIMUM POS. CHANGE(%)
8.3 0.0
5.3 0.0
0.0 13.3
14.3 0.0
8.8 0.0
9.1 0.0
0.0 0.0
3.3 0.0
3.3 0.0
0.0 0.0c
0.0 •  M
12.5 5.0
9.7 0.0
12.5 4.1
0.0 0.0
69 0.0
4.9 0.0
6.9 0.0
8.3 1.7
5.6 0.0
10.5 0.0
0.0 0.0
0 -  : no data for that particular trial 
'each sample was approximately 2 mg 
b see Scheme 6 for explanations
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TABLE 6
DATA USING CHOLINE CHLORIDE 
AND/OR ATROPINE
CONC.
CHOLINE
CHLORIDE
CONCENTRATION
ATROPINE
MAX. POS. CHANGE 
PERCENT 
F I
OVERALL 
CHANGE PERCENT 
F I
3.2x10‘®M 0 19.0 0.0 Died Died
3.2x 10 '4M 0 13.5 0.0 -37.5 -15.4
9.6x 10 '4M 0 10.6 0.0 -26.3 -
3.2x 10 '5M 0 8.3 1.7 •16.7 -18.8
3.2x 10 '5M 0 5.8 0.0 -18.4 -5.9
3.2x 10 '5M 0 13.7 0.0 -17.2 •15.0
3.2x 10'6M 0 2.5 7.4 •22.5 •4.3
0 10'®M 3.3 0.0 0.0 0.0
0 10’4M 3.4 0.0 -10.3 -4.2
0 1Q'®M 4.3 . . -8.7 —
3.2x10‘*M 5x10'®M 0.0 0.0 -14.7 -4.2
3.2x10'sM 10-4M 0.0 0.0 -12.1 -8.9
3.2x 10'5M 5x10'®M 3.3 0.0 -13.2 0.0
change fifteen minutes after addition 
•• : no data for that particular trial
TABLE 7
DATA WITH SCOPOLAMINE,
ACETYLCHOLINE, AND 
4-(1-NAPHTHYLVINYL) PYRIDINE
CONC. I SAMPLE I MAXIMUM POS. CHANGE(%) I  OVERALL A (%)
MOLARITY F I F I
10'4 Scopolamine 9.4 0.0
10'* • • 6.7 21.6
1.8x1 O’5 Acetylcholine Died Died
1.8x1 O'® n 11.9 11.5
10'4 4-(1>naphthylvlnyl)
pyridine
0 . 0 15.0
II i i 3.8 0 . 0
II i i 2.6 0 . 0
10'® • i 0 . 0 10.0
10'® i i 0 . 0 4.8
-9.4 0.0
-13.3 21.6
Died Died
•5.6 -9.2
-30.0 15.0
-35.0 -
-39.5 0.0
-16.0 -13.0
-12.0 -3.2
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TABLE 8
MISCELLANEOUS DATA
|  ■  MAX. SUDDEN CHANGE I  OVERALL CHANGE
SAMPLE I COMMENTS I PERCENT I  PERCENT
F I F I
8,11,14 - elco- methyl 0.0 0.0 -16.0 *5.0
satrlenolc acid ester
31 -VII-86-3-14 Gonads 12.1 0.0 -6.1 -34.7
I f i i 10.5 5.3 *5.3 -2.3
I f • i 6.3 0.0 -12.5 0.0
f f MeOH Phase 6.5 9.2 •12.9 0.0
f f Heptane Phase 0.0 3.9 -9.5 -9.2
ATX mixture 50 pg 0.0 7.7 •18.9 •17.9
18-2-5 Florida Tunicate 3.1 4.8 -12.5 •2.9
17-1-10
i i 2.9 7.2 -17.6 3.6
17-1-5
• i 6.3 0.0 -18.8 -15.0
17-1-6
n 2.3 8.0 •11.6 1.6
17-1-4
n 0.0 2.6 -14.3 -10.5
17-1-7
i i
6.5 6.8 -19.4 2.9
17-1-3
i i 0.0 10.0 -21.6 10.0
18-2-2
it Died Died Died Died
didemnln B 10 ng 0.0 0.0 -2.4 -8.3
i i 50 pg 0.0 2.0 •14.6 -16.1
didemnln E 10 ng 0.0 3.0 -5.3 0.0
i i 50 pg 6.7 0.0 •3.3 -12.5
29-VI-82-3-1 Agelas (IBSBE) 0.0 11.5 -22.0 10.0
26-VI-8'1 -1 -4 Neoflbularia (IREC) 2.9 4.7 -17.4 0.0
29-VI-82-2-1 Tedanla (IBSBE) -21.0 0.0 -47.0 -10.0
6-VII-81 -1 -2 Tedanla (IRCE) 3.9 -91.6 -20.8 -90.0
AHCE650 Ptllocolls 11.4 -37.4 0.0 -15.0
AHCE 583 Aplyalna 2.4 0.0 -21.4 •30.0
AHCE 628 Plakovtls 0.0 2.6 -37.5 -16.9
change fifteen minutes after addition
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was not connected to the transducer. Because glass has been shown to be 
less harsh on tissue than steel,24 small glass hooks woro made. Using 
these, the heart exhibited no loss of frequency nor amplitude after fifteen 
to twenty minutes. Some extracts were tested using the glass hooks, and 
the results were sometimes quite different than those using steel hooks 
(Table 1). Something that was apparent in almost all cases, howover, was 
that there did not seem to be many relatively large changes in either 
frequency or amplitude, but the tests showed quite clearly a rather slow 
loss or gain during the fifteen minutes in which the heart beats were 
recorded. Also, there were very few instances in which the amplitude 
actually increased for the fifteen minutes of each trial, and no such 
instances for the frequency. By only taking the frequency and amplitude 
levels at five, ten, and fifteen minutes, as previously cited,6'7 some 
potentially important data was lost because some samples seemed to 
show fairly sudden changes in the first few minutes. It is worthwhile, 
then, to record data at one minute intervals. Results of doing this and 
calculating percent changes gives some surprising results as will be 
discussed. One possible explanation for the apparent slow drifts toward 
negative changes is a change in pH of the bath,24 but this was not 
thoroughly investigated.
It was decided that before attempting to test many different extracts 
and trying to draw meaningful conclusions, the assay must be tested to at 
least qualitate its reproducibility. Norepinephrine and digoxin were 
tested so that both increases and decreases could be observed. Because 
norepinephrine is insoluble in water, norepinephrine bitartrate was used, 
but will be referred in the text simply as norepinephrine. Upon testing 
norepinephrine, the most dramatic result was that both frequency and
amplitude decreased to some extent after the first initial increase (Table 
2). In fact, at concentmtions lower than 10 5M.. both frequency and 
amplitude were at levels below their initial values Addition of 
norepinephrine to water seemed to decrease the pH of the solution, but as 
the initial response was most important, this was not teslod further. The 
results of change in frequency seem vety reproducible (within 10%) for 
the first few minutes. The dose-response curve for norepinephrine indeed 
shows that the frequency increases with increasing concentration. 
Similar qualitative results with the amplitude are also found, but to a 
lesser degree. The reason for this is most likely attributed to the 
disturbance caused by the addition of the sample and subsequent stirring 
of the bath. At the time of addition, the heart is sometimes moved thus 
changing the tension on the threads. The apparent amplitude would then be 
different from its actual value. If the heart now moves in the bath, either 
to its original position or to a different one, an apparent change in 
amplitude may not be due to the heart beating, but to its moving in the 
bath. Using the present procedure of adding the extract , giving the exact 
same disturbance to the bath is not realistic. Correcting this problem 
would undoubtedly make the operation more complicated, which is not 
advisable for an assay which is to be used in the field. The problem, 
however, is mostly quantitative as it is seen that norepinephrine 
definitely gives rise to a positive inotropic response. Therefore, this 
assay does seem to give qualitatively expected results using a pure drug. 
It does not appear unreasonable to obtain results at least relatively 
quantitative, however. For example, norepinephrine readily decomposes; 
some trials were performed on a one day old solution of norepinephrine,
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and the results relative to those with a fresh solution show the assay can 
detect differences in concenlration (Figure 5).
Next, digoxin was tested. The results at first appeared less prom­
ising than those with norepinephrine. For example, at 1 0 3M. and 10 4M., 
tnere was no increase in amplitude, yet an increase in frequency of the 
beats within the first few minutes. Because these are relatively high 
concentrations, and digoxin acts by destroying the ATPase, the amplitude 
data are not unreasonable as these concentrations are no doubt toxic to 
the heart. The increase in frequency may also be explained. At toxic 
levels of digoxin, the resting potential is decreased and the depolarization 
slope is increased.18 Although never explicitly stated, it would seem that 
the heart would be able to beat faster as the ion equilibrium potential 
would not be such a burden. Since this is a toxic concentration, the 
increase should be temporary, and it in fact is. As the concentration is 
lowered to 10'18M, the amplitude increase is observed, and the change in 
frequency is not so dramatic (Table 3). The dose-response curve shows 
this assay is relatively sensitive to small concentrations of a pure drug.
Using both norepinephrine and digoxin, a few significant observations 
were noted. First, the initial frequency of the frog's heart is rather 
important with respect to its response. The usual initial frequency is 
between 35 to 40 beats per minute. When this frequency was below 25 
beats per minute, the drugs seemed to affect the heart to a greater degree. 
Also, a battery had been useo in previous years to try to re-start a heart 
which had undergone arrest. This usually gave inconsistent, even erratic, 
results. Hearts which had stopped were revived only by applying pressure 
at regular intervals, and even then this was done sparingly. Another
observation was that by circulating the bath with a stream of oxygen as
had been done in the past, no results were obtained as this affected the 
transducer. This may cause a problem as the effective concentration 
around the heart may decrease over time; this could explain why values 
slowly decrease. If this is the case, it is not a very significant problem 
as long as this assay is able to detect a cardioactive agent and respond to 
it. Because of this, only the results within the first few minutes are 
deemed very significant. This is especially reasonable when dealing with 
toxic substances as each heart, once poisoned, may slow down or stop at 
different rates; and an examination of this is not the purpose of this 
assay.
Once the assay was trustworthy with pure drugs, it was ready to be 
tested with crude extracts. The first to be tested were samples of sea 
urchins and sea anemones collected in Maine in 1986 (Table 4). The 
results of these tests were quite startling. For example, 16 of the 18 
samples showed some type of sudden change. Also noticed was that both 
the frequency and amplitude of the heart beats slowly decreased over time 
after the initial change. The sea urchin 28-VI-86-1-5 was tested as it 
showed the greatest response of the sea urchins. Sea anemones have 
shown cardioactivity in the past, thus a finding may not be novel.25 First 
of all, the activity was shown to be reproducible. Next, the sample was 
triturated first with methylene chloride, and then with rrrthanol. This 
left a precipitate. All of these were tested, and the activity was found in 
both solvents, though not in the precipitate. A frozen sea urchin was then 
thawed, and separated into shell, digestive tract, and gonads. These were 
ground and placed in a 3:1 : methanolitoluene solution (1 g extract to 10 
mL solution). Upon assaying these, the activity seemed to be located in 
the gonads, and this result was reproducible. Next, using the extraction
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scheme shown in Scheme 8,26 the active component appeared to be rather 
polar. This scheme did not, however, effectively isolate the activity. 
Indeed, it seemed to be distributed in most fractions through the column. 
At this time, bioactive lipids from the gonads of the sea urchin 
Stronalvocentrotus droebachiensis collected in Maine were reported.2? 
These lipids are the cholesterol and triglyceride esters of 8,11,14- 
eicosatrienoic acid. The methyl ester of this acid was tested, but no 
activity was found. Data from mass spectra of the active portions of 28- 
VI-86-1 -5 showed the possibility of cholesterol and choline. High 
resolution FABMS concluded that choline is indeed present.
Because the heart is able to convert choline to acetylcholine, this 
result is quite significant. Assays performed on choline chloride gave 
results similar to those with the sea urchin under scrutiny (Figure 6). 
Acetylcholine was also tested and found to be quite active even at small 
concentrations. Although acetylcholine should give rise to negative 
inotropic and negative chronotropic responses, these results may be 
explained by a rationale similar to that explaining the effects of digoxin. 
A toxic level of acetylcholine will most likely have initial unexpected 
results on the heart. Since digitalis compounds use the release of 
acetylcholine to exhibit their negative chronotropic effects, this is not an 
unreasonable line of thought. In order to try to block the muscarinic
receptors, atropine was used. Unfortunately, reportedly effective levels
seemed to show some degree of toxicity. Testing atropine and choline 
chloride, however, did seem to abolish the initial response, although the 
toxicity was still apparent (Table 6). The frog's heart, however, is known 
to destroy atropine,8 thus, scopolamine was tested as it is not broken 
down by the heart.24 Even small levels of scopolamine appeared too toxic
for the heart, however. Thus, the hypothesis of choline indirectly causing 
the effects could not be corroborated in this manner. Next, 4-(1- 
naphthylvinyl)pyridine was tested as it is reported to destroy choline 
acetyltransferase at concentrations at around 10'5L128 Upon testing as 
low as 10 8M, this compound appeared at least as toxic as the choline 
chloride. This is not too surprising as the reported assays were done on 
homogenated rat brains, thus the toxicity the compound may have solely on 
the heart would not be observed.
Some very important conclusions may be gathered from these 
experiments. For example, if the heart allows choline to be converted to 
acetylcholine, the observation of the slow negative drift of both frequency 
and amplitude may be explained. Choline is found in all animals,24 which 
would explain the large number of samples found to exhibit some activity. 
This does, however, raise some doubt on the effectiveness of the frog 
heart assay.
As a test to see if the activity noticed in most of the sea urchins was 
similar, the sea urchin 31-VII-86-3-14 was subjected to an extraction 
similar to that of 28-VI-86-1-5, although the sample was not put through 
a column. These results show quite clearly that the activity stays almost 
exclusively in the polar phase, as seen with the other sea urchin. A 
mixture of the ATX toxins was also tested. Unfortunately, the exact 
proportions of each toxin is not known. Also, only 50 jig  were available 
for the assay. Under the assumption that the sample consisted entirely of 
ATXII, the concentration would be the minimum required to show a 
response . Because ATXI is much less potent, and ATXIII does not show any 
activity,3*4*5 it is not su'prising that no dramatic result was found. Also 
tested were some tunicates collected from Florida in 1987*88. Some
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showed results similar to those for the sea urchins and sea anemones, but 
as a whole seemed to be less active. Didemnins B and E also showed 
little, if any, activity. Finally, some sponges were tested with only one 
noticeable result : Tedania ignus (29-VI-82-2-1) gave rise to a 21% loss 
in frequency after only one minute.
Obviously, a major complication in an experiment dealing with live 
animals is the animals themselves. A few unexpected incidents served to 
slow down the project. For example, as cited, the metabolism of the 
frog's heart is somewhat dependent on days in captivity. It soon became 
readily apparent that the frogs must be kept for at least one to two days 
bf‘ io?e attempting to use their hearts for the assay. Otherwise, the initial 
frequencies were too low to be useful. Also, the beginning of the winter 
season is an extremely bad time to have to depend on using the frogs. One 
reason is that they seem to be more susceptible to nontract "red leg', a 
rather com n disease due to contaminated water. It is advisable to put 
some copper wire in the tank with the frogs and to make sure there is a 
constant supply of running water.24 Also, frogs are able to sense the 
seasons, and, unlike mice, cannot be conditioned in the laboratory 
setting.24 Thus, during late autumn, they undergo hormonal changes 
because they are trying to hibernate and they exhibit a great deal of 
hyperactivity at this time. This condition usually lasts at least a couple 
of weeks.
SUMMARY QF RESULTS
The most striking result from this research is that choline appears to 
give rise to a response in the heart, either directly, or indirectly, through 
acetylcholine. Although only one sample was definitely shown to indeed
37
contain chorine, its universal presence in animals has been known for 
quite some time.24 Also, the results of most all assays performed on 
marine samples qualitatively parallel the data found when choline 
chloride was tested. Though no conclusive evidence that choline was the 
cause of noticed effects was obtained, the hypothesis was never disproven 
either.
That choline may elicit an effect on this assay raises some question 
as to the value of this as an experimental tool. However, results from 
purified compunds seem to suggest that under certain conditions this 
assay is not only reproducible, but reacts to somes drugs as would be 
expected of a human heart. Although the results suggests that frequency 
data is more trustworthy than amplitude data, both are qualitatively 
reliable.
CONCLUSIONS
The frog heart assay appears to be an excellent method of detecting 
cardioactivity in pure samples. This has been observed with nor­
epinephrine, digoxin, and acetylcholine. Unfortunately, its potential as a 
field assay to screen crude extracts is very doubtful. One reason for this 
is that the entire heart is used, thus it is difficult to distinguish between 
actual cardioactive effects and simple toxicity to the heart. For example, 
since the heart depends on its ion channels and pumps, varying the 
concentration of certain salts will elicit a response, but there is no real 
clinical application of this. Also, if choline is indeed converted to 
acetylcholine in this assay, the sample tested must be extremely potent 
or at a high concentration to overcome this. Effects cf compounds on the 
heart are also concentration dependent, and it is unrealistic to quantitate
38
39
amounts of sample In the field. Therefore, it seems that this assay would
lend itself well as an initial test on somewhat purified unknown 
compounds.
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